Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The influence of repeated administration of poloxamer 407 on serum lipoproteins and protease activity in mouse liver and heart.

Korolenko TA, Tuzikov FV, Johnston TP, Tuzikova NA, Kisarova YA, Zhanaeva SY, Alexeenko TV, Zhukova NA, Brak IV, Spiridonov VK, Filjushina EE, Cherkanova MS, Monoszon AA.

Can J Physiol Pharmacol. 2012 Nov;90(11):1456-68. doi: 10.1139/y2012-118. Epub 2012 Nov 13.

PMID:
23181274
2.

Influence of atorvastatin and carboxymethylated glucan on the serum lipoprotein profile and MMP activity of mice with lipemia induced by poloxamer 407.

Korolenko TA, Tuzikov FV, Cherkanova MS, Johnston TP, Tuzikova NA, Loginova VM, Filjushina EE, Kaledin VI.

Can J Physiol Pharmacol. 2012 Feb;90(2):141-53. doi: 10.1139/y11-118. Epub 2012 Feb 9.

PMID:
22320860
3.

Influence of atorvastatin on fractional and subfractional composition of serum lipoproteins and MMP activity in mice with Triton WR 1339-induced lipaemia.

Korolenko TA, Cherkanova MS, Tuzikov FV, Johnston TP, Tuzikova NA, Loginova VM, Kaledin VI.

J Pharm Pharmacol. 2011 Jun;63(6):833-9. doi: 10.1111/j.2042-7158.2011.01287.x. Epub 2011 May 3.

PMID:
21585382
4.

Early-stage atherosclerosis in poloxamer 407-induced hyperlipidemic mice: pathological features and changes in the lipid composition of serum lipoprotein fractions and subfractions.

Korolenko TA, Johnston TP, Tuzikov FV, Tuzikova NA, Pupyshev AB, Spiridonov VK, Goncharova NV, Maiborodin IV, Zhukova NA.

Lipids Health Dis. 2016 Jan 22;15:16. doi: 10.1186/s12944-016-0186-7.

5.

Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.

Ryomoto KI, Suzuki M, Kanazawa A, Hasegawa M, Kimura Y, Yamamura T, Harano Y.

Am J Hypertens. 2000 Jun;13(6 Pt 1):617-24.

PMID:
10912744
6.

Serum cystatin C and chitotriosidase in acute P-407 induced dyslipidemia: Can they serve as potential early biomarkers for atherosclerosis?

Korolenko TA, Pisareva EE, Filyushina EE, Johnston TP, Machova E.

Exp Toxicol Pathol. 2015 Sep;67(9):459-66. doi: 10.1016/j.etp.2015.06.003. Epub 2015 Jun 28.

PMID:
26129870
7.
8.

Comparative characteristics of lipemia models induced by injections of Triton WR-1339 and poloxamer 407 in mice.

Loginova VM, Tuzikov FV, Tuzikova NA, Korolenko TA.

Bull Exp Biol Med. 2013 Jun;155(2):284-7.

PMID:
24131010
10.

Hyperbetalipoproteinemia with small low-density lipoprotein, a characteristic disorder of lipoprotein in essential hypertension.

Ikeda K, Suzuki M, Ikebuchi M, Hara Y, Tsushima M, Yamamoto A, Harano Y.

J Diabetes Complications. 1995 Oct-Dec;9(4):227-9.

PMID:
8573733
12.

Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.

Diabetes. 2003 Mar;52(3):803-11.

13.

Lipoprotein profile in patients who survive a stroke.

Oravec S, Krivosikova Z, Krivosik M, Gruber K, Gruber M, Dukát A, Gavorník P.

Neuro Endocrinol Lett. 2011;32(4):496-501.

PMID:
21876499
14.
15.

[Determination of fractional and subfractional blood lipoprotein compositions with small angle X-ray scattering (a comparison with a biochemical method)].

Tuzikov FV, Ragino IuI, Tuzikova NA, Ivanova MV, Galimov RV, Nikitin IuP.

Vopr Med Khim. 2002 Jan-Feb;48(1):84-93. Russian.

PMID:
12068501
16.

Effects of high cholesterol diets on rat plasma lipoproteins and lipoprotein-cell interactions.

Cole TG, Kuisk I, Patsch W, Schonfeld G.

J Lipid Res. 1984 Jun;25(6):593-603.

17.

Characterization of very low density lipoproteins and intermediate density lipoproteins of normo- and hyperlipidemic apolipoprotein E-2 homozygotes.

Schmitz G, Assmann G, Augustin J, Dirkes-Kersting A, Brennhaüsen B, Karoff C.

J Lipid Res. 1985 Mar;26(3):316-26.

18.

Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.

Berti JA, Amaral ME, Boschero AC, Nunes VS, Harada LM, Castilho LN, Oliveira HC.

Metabolism. 2001 May;50(5):530-6.

PMID:
11319713
19.
20.

Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.

Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T, Inoue T, Morii H.

Clin Nephrol. 1995 Apr;43(4):268-77.

PMID:
7606882

Supplemental Content

Support Center